Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2025
- Primary completion
- Nov 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing Induction GP+placebo group with Induction GP+toripalimab group (2 arms). Primary endpoint: Progression-free Survival at 3 years. Started Feb 2025; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06712888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712888.